Heat shock proteins and antioxidant genes involved in heat combined with drought stress responses in perennial Rye grass
"Novo Nordisk continues to explore semaglutide across metabolic and cardiovascular health, including MASH, a condition with limited treatment options for patients and healthcare professionals," said Anna Windle, PhD, senior vice president of clinical development, medical and regulatory affairs at Novo Nordisk, maker of Ozempic and Wegovy, in a press release provided to Fox News Digital
Patients on GLP-1 medications who want to maximize fat metabolism and support liver function Patients with mild weight loss goals (10-20 pounds) who prefer a lighter-touch approach Anyone seeking an energy boost even without active weight loss goals Patients concerned about liver health, particularly those with fatty liver disease Patients on hormone replacement therapy optimizing body composition Patients experiencing fatigue, brain fog, or low energy Timeline for Results Most patients notice increased energy within the first 1-2 injections, often within a day or two of their first dose
& Xu, S
In February 2025, the FDA declared that there is no longer an Ozempic shortage, and compounding pharmacies have 60 to 90 days to stop producing it, depending on the type of pharmacy or facility
